Lysosomes, with their arsenal of catabolic enzymes and crucial metabolic housekeeping functions are experiencing a revived research interest after having lived a rather quiet life for the last few decades. With the discovery of the interaction of the lysosomes with another ancient component of cellular homoeostasis, the molecular chaperone HSP70 (heat-shock protein 70), the stage seems set for further discoveries of the mechanisms regulating cellular and physiological stress responses to otherwise detrimental challenges.
Introduction
HSPs (heat-shock proteins) are the archetypal molecular chaperones whose main function is to prevent proteins from misfolding, thus serving a fundamental cytoprotective role. The HSPs are divided into subfamilies according to their molecular masses, with the 70 kDa family being the most prominent and evolutionarily conserved [1] . In this family, HSPA1A/HSP70-1, commonly referred to as simply HSP70, is the primary stress-inducible member and one of the major cytoprotective agents in the cell.
Lysosomes are acidic organelles that receive membrane traffic input from the biosynthetic, endocytic and autophagic pathways. They contain numerous acid hydrolases capable of digesting all of the major macromolecules of the cell to breakdown products available for metabolic reutilization [2, 3] . Being the primary catabolic organelle of the cell, lysosomes are also at the centre of a series of debilitating metabolic genetic disorders commonly referred to as LSDs (lysosomal storage diseases). These diseases are very rare, a testament to the crucial role of the respective affected enzymes in maintaining cellular function, but, for the majority of the LSDs, treatment is non-existent. As the name implies, the LSDs are characterized by an accumulation of substrates in the lysosomes that compromise the function and integrity of the organelle.
Importantly, previous studies have established HSP70 as a specific and central regulator of lysosomal stability in cancer [4] , and ectopic expression of HSP70 in transformed cells can reduce LMP (lysosomal membrane permeabilization), which is a major factor in many cell death programmes [4, 5] . Despite this intriguing role of LMP and HSP70 in the regulation of cell survival, very little is known about the mechanisms regulating lysosomal stability and the effect of HSP70 in the lysosomes. Discovering and studying factors involved in lysosomal stability and integrity is therefore of crucial importance, and we set out to address this further by investigating how HSP70 could bind lysosomal membranes.
Binding of HSP70 to a lysosome-specific lipid stabilizes lysosomes
It is well characterized that HSP70 can be present on plasma membranes of tumour cells, as well as in the endolysosomal system [4, 6] and that HSP70 can be released to the bloodstream during different stress-inducing events, the most typical being fever, trauma and strenuous exercise, although psychological stress has also been described to trigger release of HSP70 (reviewed thoroughly by Whitham and Fortes [7] ). In addition, the presence of HSP70 species inside the endolysosomal compartment has also been described for another member of the HSP70 family, the constitutively expressed HSC70 (heat-shock cognate 70). The function of HSC70 at this location has indeed given name to the process known as chaperone-mediated autophagy [8] .
The molecular basis for the association of HSP70 with plasma and endolysosomal membranes has, however, remained unresolved.
Our new data show that HSP70 can be efficiently endocytosed and localized to the lysosomes [9] . This is in accordance with data showing that extracellular HSP70 can bind to a number of receptors on different leucocyte subpopulations. The receptors involved in HSP70 recognition mainly include PRRs (pattern-recognition receptors) and consist of a variety of receptors from different receptor families such as the TLRs (Toll-like receptors), scavenger receptors and c-type lectins [10] . Once in the lysosomes, we found that HSP70 interacts directly with the intraluminal membranes of the organelle [9] . These numerous intraluminal membranes are one of the main characteristics of lysosomes and are derived from the ILVs (intraluminal vesicles) of late endosomes from which the lysosomes have matured [2] . The intraluminal membranes are characterized by a high concentration of BMP [bis(monoacylglycero)phosphate], a lysosome-specific anionic lipid [11, 12] which is also essential in the formation of the ILVs [13, 14] .
We have shown that HSP70, but not the closely related HSP70-2 and HSC70, modulates lysosomal stability through direct binding to BMP [9] . One of the defining properties of BMP is its negative charge and, at low pH (4.5), the ATPase domain of HSP70 is predominantly positively charged. This presumably contributes to HSP70 interaction with BMP in both large unilamellar vesicles and lipid monolayers under acidic conditions [9] . Although HSP70 has been shown previously to have affinity for other negatively charged lipids [15, 16] , this is the first time that this has been demonstrated unequivocally in a biologically relevant setting.
Our working model is that HSP70 interacts with BMP via an electrostatically positively charged wedge-like subdomain at the bottom of the ATPase cleft [9] (Figure 1 ). This is on the basis of the following: (i) the pH-dependent interaction between HSP70 and BMP; (ii) the PBD (peptide-binding domain) of HSP70 being only capable of much weaker interactions with BMP; (iii) the conservative mutation of Trp 90 to phenylalanine dramatically reducing the affinity of HSP70 to BMP; (iv) the BMP-binding properties of the ATPase domain; (v) the different isoelectric points of the PBD and ATPase domains of HSP70, and (vi) the molecular modelling of surface electrostatic potential of HSP70.
It has been proposed that HSP70 contains specific binding sites for the hydrophilic and hydrophobic parts of acidic glycolipids both in the ATPase as well as in the PBD [15] . Although this model might be applicable for HSP70 binding to acidic glycolipids, it does not fit with our data on the interaction between HSP70 and BMP [9] . However, an intermediate of the two models could explain the interaction of HSP70 with a more common anionic lipid motif. We propose that, in such a model, the positive surface charge of the ATPase domain of HSP70 could facilitate electrostatic interactions, and particular residues, such as Trp 90 , might be involved in determining specificity of binding of anionic lipid-binding partners such as BMP. Interestingly, this model can accommodate a view of HSP70 as a more general regulator of lipid homoeostasis in the cell. In support of this are data demonstrating that the lipid membranes of cells might serve as the primary sensors of stress such as fever and oxidative stress and hence as the initial inducers of the stress response [17, 18] . In the face of stress, the lipid membranes of the cell would be crucial compartments to maintain, or indeed modify, in order to have a proper cellular response to the challenge. The binding of HSP70 to lipids such as BMP and the following increased stability of lysosomal membranes and perhaps other cellular lipid events could thus represent a part of a general cellular stress response. In the case of cancer, such a response might have been hijacked to serve the cancer's own end, but also from a broader evolutionary perspective, a co-ordinated protein-lipid response in the face of cellular stress would make good sense.
Our data showing that HSP70 exclusively, and not HSC70 and HSP70-2, are capable of directly protecting lysosomal membranes argue for the notion that a potential lipid stress response might be specifically regulated by the major stress-inducible HSP70 itself and not other HSP70 species. However, further investigations are needed to establish precisely which molecular chaperones, and indeed other stress-induced proteins, contribute to the protection of the lysosomes.
ASM (acid sphingomyelinase) is a key component in HSP70-BMP-mediated lysosomal stabilization
Interestingly, in addition to its structural role in internal lysosomal membranes, BMP is an important binding site for enzymes and cofactors involved in lysosomal catabolism of sphingolipids [11, 12] . As such, it serves as a stimulatory cofactor for enzymatic hydrolysis of not only SM (sphingomyelin) via ASM, but of most membranebound sphingolipids, as it also functions as a cofactor for SAPs (sphingolipid activator proteins)/saposins A-D and ganglioside GM2 activator protein [19, 20] .
Sphingolipids form a class of lipids that, together with glycerophospholipids and cholesterol, make up the lipids of all eukaryotic membranes [21] . There are two main types of complex sphingolipids: the structurally diverse glycosphingolipids in which the backbone ceramide is bound to a wide variety of different carbohydrates [22] , and SM, which contains a phosphocholine headgroup [23] . De novo synthesis of the sphingolipid backbone takes place in the ER (endoplasmic reticulum), whereas the downstream formation of the more complex sphingolipids continues in the Golgi apparatus [24] . Catabolism of sphingolipids occurs in the lysosome and ultimately yields sphingosine, which can be reused to form new complex sphingolipids via the 'salvage pathway' [25] . The importance of a functional lysosomal sphingolipid catabolism can be easily appreciated by the fact that clinical diseases are apparent in the case of dysfunction of any of the lysosomal sphingolipid-catabolizing enzymes. This gives rise to relatively rare, but severe, diseases such as Tay-Sachs, Sandhoff, Farber, Fabry, Gaucher, Krabbe and Niemann-Pick diseases, the so-called sphingolipidoses, where non-degradable lipids accumulate inside cells and give rise to a signature cellular morphology characterized by the vast accumulation of lysosomes [9, 26] (Figure 2) .
In this context, one of the best studied enzymes is ASM, which hydrolyses SM to ceramide, and dysfunction of ASM leads to the aforementioned detrimental lysosomal storage diseases Niemann-Pick disease Type A and B. ASM activity depends on its direct binding to BMP through its saposin domain [27] , and, when this interaction is disrupted, ASM is allegedly proteolytically degraded by lysosomal proteases [28] .
In order to look deeper into the biological role of the HSP70-BMP interaction and its possible therapeutic perspectives, we thus decided to look at the effect of rHSP70 (recombinant HSP70) on the binding between ASM and BMP. Surprisingly, HSP70 is capable of modulating the binding of ASM to BMP-containing liposomes at pH 4.5, depending on the concentration of HSP70. Low concentrations (3-150 nM) of pre-bound HSP70 facilitate the interaction of ASM with BMP-HSP70 liposomes, whereas higher concentrations of HSP70 (300-1500 nM) compete with ASM for the binding to BMP [9] . A direct translation of such an in vitro result is, of course, challenging, given that the specific intralysosomal concentration of HSP70 in an in vivo setting is impossible to determine. However, the HSP70-mediated increase in ASM-BMP binding is reflected by increased ASM activity upon treatment of MEFs (mouse embryonic fibroblasts) with HSP70, as well as in MEFs transgenic for human HSP70, clearly demonstrating that, in vivo, HSP70 facilitates ASM binding to BMP [9] .
Remarkably, both pharmacological and genetic inhibition of ASM destabilize lysosomal membranes, suggesting that ASM activation is likely to play a crucial role in the HSP70-mediated stabilization of lysosomes [9] .
HSP70 and sphingolipid catabolism: mechanistic insight into lysosomal stability
In addition to its presence at the internal membranes of the lysosomes, ASM can also be exported to the cell surface [27] . Here, ASM can mediate assembly of signalling complexes in ceramide-rich membrane domains, which accounts for many of its reported pro-death functions [29] . The lack of BMP on the plasma membrane and the clear absence of HSP70 on the plasma membrane in our studies [9] , however, suggests that the HSP70-mediated rise in ASM activity is a lysosomespecific effect. A central question regarding the protective role of HSP70 on lysosomes thus remains: how can the presence of a molecular chaperone affect the stability of a whole organelle? On the basis of our data that HSP70 increases ASM activity, we suggest that a change in the lipid composition of inner lysosomal membranes has a direct and potent influence on the stability of the entire lysosome. Whether this is due to a direct effect on the outer lysosomal membrane, or by other indirect means, is presently unknown. One hypothesis could be that, since generation of ceramide greatly alters the properties of membranes [30] , an ASM-dependent increase in lysosomal ceramide content could in itself have a positive impact on the stability of the outer membrane. Alternatively, lower levels of the ASM substrate SM might be the crucial factor.
Sphingolipid composition of ILVs in late endosomes is decisive for whether they end up as exosomes or as internal membranes in lysosomes [31] . Thus it is important to remember that the lysosomes are far from being static organelles, but rather a part of a highly dynamic endocytic system of membranes with continuous membrane fusions and budding [2, 3] . HSP70 and ASM could therefore influence the properties of a whole set of dynamic endocytic membranes in a way that ultimately has a positive effect on lysosomal integrity.
A possible novel therapy for LSDs?
Finally, and perhaps most importantly, we found that the dramatic increase in lysosomal volume and decrease in lysosomal stability associated with reduced ASM activity in cells from patients with Niemann-Pick disease can be effectively corrected by treatment with rHSP70 [9] ( Figure 2B ). Treatment of primary fibroblasts from patients suffering from both type A and B Niemann-Pick disease with rHSP70 led to an increase in the residual activity of ASM, reduction in SM burden and, most importantly, correction of the pathological lysosomal morphology.
Together with previous observations that exogenously added HSP70 could have therapeutic potential towards neuronal damage [32, 33] , this opens up the possibility of investigating the potential beneficial effects of rHSP70 in the treatment of Niemann-Pick disease, as well as other LSDs. Of particular note, it cannot be ruled out that HSP70 influences additional enzymes, since multiple lysosomal sphingolipidand phospholipid-degrading enzymes require anionic lipids, particularly BMP [11, 19, 34, 35] , and HSP70 binds specifically to BMP [9] . On the other hand, ASM is special in the sense that it binds directly to BMP, whereas most other lipases do so via essential co-factors such as GM2 activator protein and saposins [11, 12] . It is thus not yet known whether HSP70 has a positive effect on binding between BMP and the various activator proteins. Additionally, the ceramide species generated by different enzymes such as ASM and GBA1 (acid β-glucosidase 1), are not necessarily identical, and might have different effects on lysosomal stability.
Moreover, rHSP70 endocytosis is presumably not dependent on M6PR (mannose 6-phosphate receptor)-mediated uptake and is capable of binding to a number of receptors on different leucocyte populations, including macrophages [7, 10] . This aspect of HSP70 biology could be of clinical importance, as M6PR-mediated uptake is defective in ASMdeficient macrophages, one of the hallmark affected cell types of Niemann-Pick disease [36] [37] [38] .
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